Clinical trials: Acute Hepatitis
Acute-on-chronic Hepatitis B Liver Failure
Study of the Model to Predict 3-month Mortality Risk of Acute-on-chronic Hepatitis B Liver Failure
This study was to predict 3-month mortality risk of acute-on-chronic hepatitis B liver failure (ACHBLF) on an individual patient level using artificial neural network (ANN) system.
- Trial name
- NCT01826760
- Testing
- Using training and testing groups to construct ANN based on laboratory tests
- Where
- China
- Volunteers
- 583 people, healthy volunteers welcome
- Sponsor
- Wenzhou Medical University
Acute Alcoholic Hepatitis, Chemical and Drug Induced Liver Injury
Digoxin In Treatment of Alcohol Associated Hepatitis
Prospective, single center, open label, randomized controlled trial to explore whether digoxin treatment affects cytokine levels as biomarkers of inflammation in patients with acute alcohol associated hepatitis, digoxin…
- Conditions
- Acute Alcoholic Hepatitis, Chemical and Drug Induced Liver Injury, Alcohol-Induced Disorders, Steatohepatitis Caused by Ingestible Alcohol
- Trial name
- DIGIT-AlcHep (NCT05014087)
- Testing
- Intravenous digoxin
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Yale University
Hypoxic Hepatitis, Ischemic Hepatitis
Molecular Adsorbent Recirculating System (MARS®) in Hypoxic Hepatitis
Hypoxic hepatitis (HH) is reported to be the most frequent cause of elevated aminotransferase levels in hospital. Up to 10 % of critically ill patients develop HH during the course of their intensive care unit (ICU) stay.
- Conditions
- Hypoxic Hepatitis, Ischemic Hepatitis, Shock Liver, Hypoxic Liver Injury
- Trial name
- MARS in HH (NCT01690845)
- Testing
- MARS
- Where
- 2 sites in Austria, Germany
- Volunteers
- 40 people
- Sponsor
- Medical University of Vienna
Acute Hepatitis C
Treatment of Recently Acquired Hepatitis C Virus Infection
To determine whether response guided treatment with pegylated interferon +/- ribavirin is effective for the treatment of recently acquired hepatitis C infection.
- Trial name
- ATAHC-II (NCT01336010)
- Testing
- Peginterferon alfa-2a, Ribavirin
- Where
- 8 sites in Australia
- Volunteers
- 82 people
- Sponsor
- Kirby Institute
Acute on Chronic Liver Failure, Hepatitis B
Randomized Controlled Trial of Tenofovir in Patients of Reactivation of Hepatitis B Presenting as Acute on Chronic Liver Failure
Background: Reactivation of hepatitis B is a well-characterized syndrome marked by the abrupt reappearance or rise of hepatitis B virus (HBV) DNA in the serum of a patient with previously inactive or resolved HBV infection.
- Trial name
- ACLF (NCT01074645)
- Testing
- Tenofovir disoproxil fumarate (TDF)
- Where
- India
- Volunteers
- 27 people
- Sponsor
- Govind Ballabh Pant Hospital
Liver Transplant, Hepatitis C
Proteogenomic Monitoring and Assessment of Liver Transplant Recipients
This study is being done to test blood, urine and tissue samples to see if this can help decide if CKD (Chronic Kidney Disease), AR (Acute Rejection) and HCV (Hepatitis C Virus) can be identified in its early stages.
- Conditions
- Liver Transplant, Hepatitis C, Chronic Kidney Disease, Acute Rejection
- Trial name
- "Mini-Liver" (NCT01644903)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Northwestern University
Acute Hepatitis A, Acute Hepatitis B
Randomized Placebo-controlled Trial Evaluating the Safety and Efficacy of Silymarin Treatment in Patients With Acute Viral Hepatitis
The purpose of this study is to assess whether two higher doses (280mg or 420mg three times daily)of silymarin therapy are safe and tolerable, and shorten the illness in patients with acute viral hepatitis compared to placebo.
- Conditions
- Acute Hepatitis A, Acute Hepatitis B, Acute Hepatitis C, Acute Hepatitis E
- Trial name
- NCT00755950
- Testing
- Silymarin, Lactose monohydrate
- Where
- 3 sites in Egypt
- Volunteers
- 70 people
- Sponsor
- University of Maryland, Baltimore
Acute Hepatitis C, HIV
Short Duration Therapy of Acute Hepatitis C Genotypes 1 or 4
The purpose of this study is to assess the rate of sustained virological response (SVR) 12 weeks after 8-week oral treatment with grazoprevir 100mg/elbasvir 50mg (MRK-combo) in patients with acute hepatitis C genotype1 or 4.
- Trial name
- SAHIV (NCT02886624)
- Testing
- Grazoprevir/Elbasvir
- Where
- 6 sites in France
- Volunteers
- 30 people
- Sponsor
- Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba
Alcoholic Hepatitis
N-Acetylcysteine in Severe Acute Alcoholic Hepatitis
Acute alcoholic hepatitis (AAH) is the most severe form of alcoholic liver disease (ALD) and is associated with a high risk of dying in the short term.
- Trial name
- NCT00962442
- Testing
- N-Acetylcysteine
- Where
- Belgium
- Volunteers
- 44 people
- Sponsor
- Erasme University Hospital
Hepatitis C Infection With HIV Co-Infection
Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed-Dose Combination (FDC) for 6 Weeks in Adults With Acute Genotype 1 or 4 Hepatitis C Virus (HCV) and Chronic Human Immunodeficiency Virus (HIV)-1 Co-Infection
The primary objectives of this study are to determine the antiviral efficacy, safety, and tolerability of ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) in adults with acute genotype 1 or 4 hepatitis C virus (HCV)…
- Trial name
- NCT02457611
- Testing
- LDV/SOF
- Where
- 4 sites in Germany, United Kingdom
- Volunteers
- 26 people
- Sponsor
- Gilead Sciences
Acute-On-Chronic Liver Failure
Risk Factors Affecting MSC Efficacy in ACLF Patients
Mesenchymal stromal cells (MSCs) are potential therapy for many diseases, with the ability of tissue regeneration, repair and immunomodulation. Acute-on-chronic liver failure (ACLF) is a severe disease with high mortality.
- Trial name
- NCT07198854
- Testing
- Not applicable- observational study
- Where
- China
- Volunteers
- 446 people
- Sponsor
- Sun Yat-sen University
Chronic-on-acute Liver Failure
Efficacy and Economic Evaluation of Nonbiological Artificial Liver Therapy in Acute-on-chronic Hepatitis B Liver Failure.
This was a non-blinded, prospective clinical study. From June 2020 to October 2021, 254 patients with HBV-ACLF were treated at the Department of Infectious Diseases, Xiangya Hospital, Central South University (Changsha, China).
- Trial name
- NCT05392673
- Testing
- KM-8800 plasma exchange device (Kuraray, Tokyo, Japan)
- Where
- China
- Volunteers
- 186 people
- Sponsor
- Xiangya Hospital of Central South University
Alcoholic Hepatitis, Acute Liver Failure
Outcomes Using MARS for Patients With ALF
Retrospective chart review will be conducted on patients at Methodist Dallas Medical Center, meeting the inclusion criteria from January 1, 2019 to December 15, 2020 to determine the transplant free survival and overall survival…
- Trial name
- NCT05594953
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Methodist Health System
Acute Alcoholic Hepatitis
Randomized, Open-Label, Multicenter, Controlled, Pivotal Study to Assess Safety and Efficacy of ELAD in Subjects w/ AILD
The primary objective of the study is to evaluate safety and efficacy of ELAD with respect to overall survival of subjects with a clinical diagnosis of alcohol-induced liver decompensation (AILD) through at least Study Day 91.
- Trial name
- NCT02612428
- Testing
- ELAD System, Standard of Care (Control)
- Where
- 44 sites in United States, Austria and 4 more
- Volunteers
- 151 people
- Sponsor
- Vital Therapies, Inc.
Hepatitis, Liver Diseases
Evaluation of Orthohepevirus C Infection as an Emerging Cause of Zoonotic Origin Disease
The main objective of this study is to evaluate the prevalence and the clinical impact of Orthohepevirus C infection in different human populations, and to determine its zoonotic origin comparing the sequences obtained in both…
- Conditions
- Hepatitis, Liver Diseases, Acute Hepatitis, Chronic Hepatitis
- Trial name
- NCT05062967
- Where
- 10 sites in Spain
- Volunteers
- 3,257 people
- Sponsor
- Maimónides Biomedical Research Institute of Córdoba
Hepatitis, Pharmacology
A Partial Randomized, Single-blind or Open-label, Dose-escalation With Multiple-dose Design Study to Evaluate the Pharmacokinetics of Acetaminophen and Its Toxic Metabolites With Panadol® and SafeTynadol® in Healthy Volunteers
To investigate and compare the possible response of Panadol® and SafeTynadol® formulations in healthy volunteers and the safety in SafeTynadol® dose-limiting hepatotoxicity.
- Trial name
- NCT05563961
- Testing
- Panadol®, SafeTynadol®
- Where
- Taiwan
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Sinew Pharma Inc.
Fulminant Hepatic Failure
Steroids in Fulminant Hepatitis A in the Pediatric Age Group
Fulminant hepatic failure (FHF) in children is a potentially devastating disease. The mortality rate may reach 80-90% in the absence of liver transplantation.
- Trial name
- NCT02375867
- Testing
- prednisolone, methylprednisolone
- Where
- Egypt
- Volunteers
- 33 people
- Sponsor
- National Liver Institute, Egypt
Hepatitis E
HEV in Patients With Acute Non-A, Non-B, Non-C Hepatitis in Al-Rajhy University Hospital for Liver
Hepatitis E is the fifth known human viral hepatitis and is probably the most common cause of acute viral hepatitis in the world.
- Trial name
- NCT03488589
- Testing
- serum samples for HEV RNA PCR
- Volunteers
- 150 people
- Sponsor
- Mahmoud Abdel Rahman
Hepatitis C
Australian Trial in Acute Hepatitis C
Australian Trial in Acute Hepatitis C (ATAHC) A prospective non-randomised dual arm longitudinal cohort of newly acquired hepatitis C infection into which participants will be enrolled and then followed at 3 monthly intervals…
- Trial name
- NCT00192569
- Testing
- Pegylated Interferon alfa 2a, Ribavirin (HIV conifected patients only)
- Where
- 18 sites in Australia
- Volunteers
- 167 people
- Sponsor
- Kirby Institute
Acute Liver Failure
Registry Protocol for Tracking Trial Subjects After VTI-206 Study Completion
VTI-207 (NCT01452295) is designed to follow subjects, both treated and control, for five years after their completion of study participation in protocol VTI-206 (NCT00973817) to gather information relating to the incidence of…
- Trial name
- NCT01452295
- Testing
- ELAD (Extracorporeal Liver Assist System)
- Sponsor
- Vital Therapies, Inc.